Your browser is no longer supported. Please, upgrade your browser.
TCON TRACON Pharmaceuticals, Inc. weekly Stock Chart
TRACON Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-5.87 Insider Own1.40% Shs Outstand6.39M Perf Week-4.42%
Market Cap9.26M Forward P/E- EPS next Y-2.65 Insider Trans405.64% Shs Float5.32M Perf Month-12.63%
Income-19.50M PEG- EPS next Q-0.71 Inst Own26.60% Short Float2.29% Perf Quarter-13.93%
Sales- P/S- EPS this Y42.40% Inst Trans3.12% Short Ratio0.25 Perf Half Y-59.67%
Book/sh0.47 P/B3.68 EPS next Y10.20% ROA- Target Price- Perf Year-66.73%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range0.95 - 6.10 Perf YTD-26.07%
Dividend- P/FCF- EPS past 5Y-4.90% ROI- 52W High-71.64% Beta1.92
Dividend %- Quick Ratio1.60 Sales past 5Y- Gross Margin- 52W Low82.11% ATR0.14
Employees19 Current Ratio1.60 Sales Q/Q- Oper. Margin- RSI (14)44.33 Volatility7.08% 7.58%
OptionableNo Debt/Eq1.50 EPS Q/Q- Profit Margin- Rel Volume0.39 Prev Close1.66
ShortableYes LT Debt/Eq0.93 EarningsAug 05 AMC Payout- Avg Volume487.89K Price1.73
Recom2.20 SMA20-4.23% SMA50-9.78% SMA200-31.38% Volume192,537 Change4.22%
Dec-23-19Reiterated H.C. Wainwright Buy $15 → $18
Mar-01-19Reiterated Needham Buy $7
Jun-13-17Reiterated Stifel Buy $14 → $6
Dec-21-16Initiated Jefferies Buy $10
Feb-01-16Resumed Oppenheimer Outperform
Jul-29-15Initiated ROTH Capital Buy $18
Mar-02-15Reiterated Stifel Buy $16 → $20
Mar-02-15Reiterated Oppenheimer Outperform $22 → $26
Feb-24-15Initiated Stifel Buy $16
Feb-24-15Initiated Oppenheimer Outperform $22
Aug-05-20 04:05PM  
Aug-03-20 08:05AM  
Jul-29-20 04:05PM  
Jul-16-20 08:15AM  
Jul-13-20 08:15AM  
Jun-22-20 02:19PM  
Jun-11-20 10:56PM  
Jun-05-20 02:48PM  
Jun-01-20 08:05AM  
May-29-20 08:20AM  
May-14-20 08:32AM  
May-13-20 04:04PM  
May-11-20 08:15AM  
May-06-20 04:05PM  
Apr-24-20 08:15AM  
Apr-14-20 08:15AM  
Apr-06-20 08:15AM  
Mar-19-20 08:15AM  
Mar-18-20 03:29AM  
Mar-16-20 08:15AM  
Mar-09-20 07:40PM  
Feb-28-20 07:28AM  
Feb-27-20 04:03PM  
Feb-20-20 06:00PM  
Feb-07-20 08:05AM  
Jan-20-20 01:14PM  
Dec-22-19 05:10PM  
Dec-20-19 08:58AM  
Nov-21-19 09:37PM  
Nov-08-19 08:05AM  
Nov-05-19 04:05PM  
Oct-29-19 04:15PM  
Oct-21-19 08:05AM  
Oct-07-19 12:40PM  
Sep-03-19 08:05AM  
Aug-29-19 08:05AM  
Aug-28-19 08:05AM  
Aug-07-19 04:02PM  
Aug-01-19 11:33AM  
Jul-31-19 04:05PM  
Jul-29-19 08:05AM  
Jul-02-19 08:05AM  
Jun-27-19 11:40AM  
Jun-07-19 01:23PM  
May-30-19 08:05AM  
May-15-19 01:31PM  
May-14-19 06:57PM  
May-07-19 04:05PM  
Apr-12-19 10:45AM  
Mar-27-19 08:05AM  
Mar-07-19 01:08PM  
Mar-01-19 02:30PM  
Feb-28-19 04:02PM  
Feb-21-19 04:03PM  
Jan-22-19 08:30AM  
Dec-31-18 07:35AM  
Dec-27-18 08:35AM  
Dec-26-18 04:05PM  
Dec-21-18 08:10AM  
Dec-04-18 07:00PM  
Dec-03-18 08:35AM  
Nov-29-18 02:01AM  
Nov-19-18 08:35AM  
Nov-15-18 08:35AM  
Nov-14-18 09:04AM  
Nov-13-18 08:20AM  
Nov-08-18 12:58PM  
Nov-07-18 06:54PM  
Oct-31-18 04:02PM  
Oct-15-18 01:00PM  
Sep-12-18 04:27PM  
Sep-10-18 09:00AM  
Aug-29-18 04:05PM  
Aug-08-18 07:19PM  
Aug-01-18 04:05PM  
Jun-13-18 08:00AM  
Jun-11-18 12:12PM  
May-31-18 04:10PM  
May-30-18 08:00AM  
May-09-18 06:03PM  
May-02-18 04:05PM  
Apr-09-18 08:00AM  
Mar-23-18 08:30AM  
Mar-21-18 04:05PM  
TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer and wet age-related macular degeneration (AMD). Its lead product candidate is TRC105, an endoglin antibody, which is in randomized Phase III clinical trial for angiosarcoma; Phase I/II clinical trial for hepatocellular carcinoma; Phase I clinical trial for lung cancer; Phase I/II clinical trial for breast cancer; Phase II clinical trials for prostate cancer; and randomized Phase II clinical trial for wet AMD. The company also develops TRC102, a small molecule that is in Phase II clinical trial for mesothelioma, Phase I clinical trial for solid tumors and lung cancer, and Phase I/II clinical trial for solid tumors and lymphomas; and TRC253, a small molecule high affinity competitive inhibitor of wild type androgen receptor (AR) and multiple AR mutant receptors that is in Phase I/II clinical trial for the treatment prostate cancer. In addition, it is developing TJ004309, a novel humanized antibody against CD73 that is in Phase I clinical trial to treat patients with solid tumors through a strategic collaboration and clinical trial agreement with I-Mab Biopharma. The company has license agreements with Ambrx, Inc.; Santen Pharmaceutical Co. Ltd.; Roswell Park Cancer Institute and Health Research Inc.; Case Western Cancer Center; and Lonza Sales AG, as well as a cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was founded in 2004 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
THEUER CHARLESPresident and CEOJun 24Buy1.909,89518,80171,714Jun 25 05:46 PM
PELLETIER SAUNDRA LDirectorJun 15Buy2.073,0006,2095,500Jun 16 05:24 PM
PELLETIER SAUNDRA LDirectorJun 11Buy2.002,5005,0002,500Jun 16 05:24 PM
THEUER CHARLESPresident and CEOMay 22Buy1.9010,59220,11961,819May 26 05:00 PM
THEUER CHARLESPresident and CEOMar 13Buy1.134,1004,62450,877Mar 13 06:21 PM
THEUER CHARLESPresident and CEOMar 12Buy1.1810,00011,80346,777Mar 12 04:32 PM
THEUER CHARLESPresident and CEOMar 11Buy1.6810,00016,83736,777Mar 12 04:32 PM
THEUER CHARLESPresident and CEOMar 10Buy1.8710,00018,69126,777Mar 10 06:02 PM
WIGGINS MARK CChief Business OfficerJan 23Buy4.025,00020,1035,000Jan 24 04:10 PM
Puissance Cross-Border Opportu10% OwnerDec 09Sale2.92340,134993,19176,048Dec 11 10:47 AM